Skip to navigation Skip to content

Clinical Trial: Telehealth Cognitive Behavioral Therapy for Insomnia


Type of MS: RRMS
Treatment mode of action: To improve sleep and fatigue
Number of Subjects: 15
Medication: Cognitive Behavioral Therapy for Insomnia via Telehealth (video conference platform)
Location: Alabama|Alaska|Arizona|Arkansas|California|Colorado|Connecticut|Delaware|District of Columbia|Florida|Georgia|Hawaii|Idaho|Illinois|Indiana|Iowa|Kansas|Kentucky|Louisiana|Maine|Maryland|Massachusetts|Michigan|Minnesota|Mississippi|Missouri|Montana|Nebraska|Nevada|New Hampshire|New Jersey|New Mexico|New York|North Carolina|North Dakota|Ohio|Oklahoma|Oregon|Pennsylvania|Rhode Island|South Carolina|South Dakota|Tennessee|Texas|Utah|Vermont|Virginia|Washington|West Virginia|Wisconsin|Wyoming
Institutions: University of Kansas Medical Center, Kansas City, KS Contact Information
Catherine (Katie) Siengsukon


NIH Clinical and Translational Science Award 


Insomnia is a prevalent issue in people with MS, and the best method to treat insomnia in people with MS remains unknown. Cognitive behavioral therapy for insomnia (CBT-I) has been shown to be an effective treatment in individuals with insomnia. However, there are limited number of individuals trained to provide CBT-I, particularly in rural areas. Therefore, the purpose of this study is to assess the use of CBT-I delivered using a video conference platform (Zoom) to improve sleep and fatigue in individuals with relapsing-remitting MS with symptoms of insomnia.

Participation will last approximately 8 weeks. The study is conducted completely through the internet; there are no visits to the laboratory. You will complete a consent form and questionnaires through a secure internet site.  You will then participate in weekly sessions that last 45-60 minutes with a trained CBT-I provider using a video conference platform (Zoom) for 6 weeks. You will then be asked to complete the same questionnaires that you did at the beginning of the study. Participants are compensated for completing the study. 


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.